News

Medigene provides Q2 update and 6M report 2020

SHOW RELEASE

Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers

SHOW RELEASE

Medigene's PD1-41BB switch receptor enhances TCR-T cell activity towards solid tumors

SHOW RELEASE

Medigene participates at upcoming virtual conferences

SHOW RELEASE

Medigene provides Q1 2020 update

SHOW RELEASE

Medigene was granted two patents for novel CrossTAg-1 technology

SHOW RELEASE

Medigene provides results for fiscal year 2019 and outlook

SHOW RELEASE

Phio Pharmaceuticals and Helmholtz Zentrum München Announce Collaboration and Option Agreement with Medigene

SHOW RELEASE

Medigene participates at upcoming conferences

SHOW RELEASE

Medigene, IRICoR and Université de Montréal sign collaboration and exclusive licensing option on novel cancer antigens

SHOW RELEASE

Positive final 2-year topline data in completed DC vaccine Phase I/II trial in AML patients

SHOW RELEASE

Interim 1-year clinical immune monitoring data from DC vaccine trial in AML presented at ASH 2019 Annual Meeting

SHOW RELEASE

Medigene reports financial & business results for the first nine months of 2019

SHOW RELEASE

Immune monitoring data from phase I/II clinical trial with DC vaccines in AML to be presented at ASH conference

SHOW RELEASE

Medigene to present on neoantigens as targets for TCR-T cell-based therapies at 2019 SITC Annual Meeting

SHOW RELEASE